SuperworthOpko Health profit margin OPK
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −12.4%
- Operating margin, 12 months
- −8.2%
- Net margin on a year earlier
- +14.3 pts
- Peer median
- 10.9%
Over the twelve months to Jun 30, 2026, Opko Health kept −12.4% of its revenue as net profit, with an operating margin of −8.2% and a gross margin of 40.8%.
Five years earlier its net margin was 3.7%.
The median for 10 large drugmakers of a similar size is 10.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −37.2% | −19.3% | 33.9% |
| FY2024 | −7.5% | −21.3% | 30.6% |
| FY2023 | −21.9% | −18.2% | 36.8% |
| FY2022 | −32.7% | −22.5% | 28.7% |
| FY2021 | −1.7% | 1.1% | 32.8% |
| FY2020 | 2.1% | 4.0% | 37.7% |
| FY2019 | −34.9% | −30.4% | 36.5% |
| FY2018 | −15.5% | −17.3% | 38.9% |
| FY2017 | −31.6% | −28.6% | 35.8% |
| FY2016 | −2.1% | −6.0% | 49.9% |
| FY2015 | −6.1% | −20.0% | 52.2% |
| FY2014 | n/a | n/a | 47.3% |
| FY2013 | n/a | −82.5% | 49.4% |
| FY2012 | −61.8% | −79.2% | 40.7% |
| FY2011 | −4.6% | −82.9% | 38.4% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −12.4% | +14.3 pts | −8.2% | |
| Q1 FY26 | −36.6% | −31.0 pts | −17.4% | |
| Q4 FY25 | −37.2% | −29.7 pts | −19.3% | |
| Q3 FY25 | −28.1% | −9.3 pts | −17.5% | |
| Q2 FY25 | −26.7% | +7.3 pts | −22.0% | |
| Q1 FY25 | −5.7% | +25.9 pts | −21.4% | |
| Q4 FY24 | −7.5% | +14.4 pts | −21.3% | |
| Q3 FY24 | −18.8% | +5.1 pts | −26.4% | |
| Q2 FY24 | −33.9% | −9.8 pts | −37.2% | |
| Q1 FY24 | −31.6% | +0.3 pts | −24.7% | |
| Q4 FY23 | −21.9% | +10.8 pts | −18.2% | |
| Q3 FY23 | −23.9% | +2.0 pts | −16.5% |
Against its peers
Companies in Drug Manufacturers - General nearest Opko Health's size, closest first, today.
| Company | Profit margin |
|---|---|
| OPKOpko Health | −12.4% |
| OMEROmeros | n/m |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| PCRXPacira BioSciences | 2.0% |
| ANABAnaptysbio | n/m |
| PAHCPhibro Animal Health | 6.6% |
| ANIPANI Pharmaceuticals | 11.1% |
| ABUSArbutus Biopharma | 84.2% |
| COLLCollegium Pharmaceutical | 5.9% |
| HRMYHarmony Biosciences | 18.9% |
| PBHPrestige Consumer Healthcare | 15.6% |
| Peer median | 10.9% |
Where Opko Health ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Opko Health
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.